Opportunity Information: Apply for RFA AR 20 001
The NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) funding opportunity RFA-AR-20-001, titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)," supports time-sensitive, hypothesis-driven mechanistic research that can be added onto an already funded and actively running clinical project. The central idea is to take advantage of existing patient cohorts, established clinical infrastructure, and the ongoing flow of clinical data and biospecimens to answer mechanistic questions that would be difficult, slow, or expensive to launch as a brand-new standalone study. While the parent project can be an interventional clinical trial or a non-interventional clinical study (such as an observational cohort), the application under this FOA must be for an ancillary mechanistic study and cannot propose a new clinical trial as the funded activity.
The funded ancillary work is expected to be tightly linked to the parent clinical project in a way that meaningfully increases the scientific value of that parent effort. In practical terms, NIAMS is looking for studies that use the parent project’s well-characterized participants, protocols, data systems, and sample collection pipelines to conduct deeper mechanistic investigations, such as interrogating disease pathways, immune mechanisms, tissue biology, biomarker dynamics, or other biologic processes relevant to NIAMS mission areas (arthritis and rheumatic diseases, musculoskeletal biology and disorders, and skin biology and diseases). The parent project is expected to already be positioned to provide what the ancillary study needs: access to participants, existing or prospectively collected clinical data, and biological samples (or the ability to collect them during the ongoing study window). Because the opportunity is designed around time sensitivity, the FOA also emphasizes an accelerated review and award process, aiming to move strong applications forward quickly so investigators can capture perishable opportunities tied to the timeline of the ongoing clinical project.
This FOA is essentially a “leverage what already exists” mechanism. NIAMS is trying to maximize return on investment by enabling researchers to build on resources that are already paid for and operational, rather than duplicating recruitment, site setup, and data collection in a separate grant. The intended payoff is a better mechanistic understanding of diseases or organ systems within NIAMS’s portfolio, with the downstream potential to uncover new diagnostic markers, therapeutic targets, or prevention strategies. In other words, NIAMS is not just funding add-on measurements for their own sake; it is funding mechanistic add-ons that can sharpen interpretation of clinical outcomes and expand the translational impact of the parent project.
From an eligibility standpoint, the FOA is broad and includes many types of U.S.-based organizations: state, county, city, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. It also explicitly includes a range of mission-relevant and underserved-serving institution types and community-connected entities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, and certain tribal governments and tribal organizations. U.S. territories or possessions are also listed among eligible applicant categories.
At the same time, there are clear limitations related to foreign involvement. Non-domestic (non-U.S.) entities and non-U.S. institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are not eligible to apply. However, “foreign components” as defined by NIH policy are allowed, meaning a U.S. applicant may include specific foreign activities or collaborations when justified and consistent with NIH rules, even though the primary applicant organization must be domestic.
Administratively, this is an R01 grant mechanism under the NIH “Health” activity category (CFDA 93.846), and it is labeled “Clinical Trial Not Allowed,” reinforcing that the proposed R01 project itself must not be a clinical trial. The opportunity lists an award ceiling of $300,000 (as provided in the source text) and had an original closing date of December 1, 2020. The overall structure signals that NIAMS wants focused, mechanistically rich ancillary aims that can be completed efficiently by piggybacking on a parent project already in motion, producing interpretable biological insight that complements and elevates the original clinical study.Apply for RFA AR 20 001
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
- This funding opportunity was created on 2019-04-25.
- Applicants must submit their applications by 2020-12-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIAMS RFA-AR-20-001 (Mechanistic Ancillary Studies to Ongoing Clinical Projects, R01 Clinical Trial Not Allowed)
What is RFA-AR-20-001 funding?
RFA-AR-20-001 is a NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) funding opportunity that supports time-sensitive, hypothesis-driven mechanistic research that can be added onto an already funded and actively running clinical project. It is meant to leverage existing cohorts, infrastructure, clinical data flow, and biospecimens to answer mechanistic questions that would be difficult, slow, or expensive to address through a new standalone study.
What does "Mechanistic Ancillary Studies" mean in this opportunity?
In this context, an ancillary study is an add-on research project that is tightly linked to a parent clinical project and increases that project's scientific value. "Mechanistic" means the ancillary work is focused on biological mechanisms (for example, disease pathways, immune mechanisms, tissue biology, or biomarker dynamics) relevant to NIAMS mission areas.
What is the parent clinical project requirement?
The ancillary study must attach to a parent clinical project that is already funded and actively running. The parent project should already have the participants, protocols, data systems, and sample collection pipelines (or the ability to collect samples during the ongoing study window) needed for the ancillary mechanistic aims.
Can the parent project be an interventional clinical trial?
Yes. The parent project can be an interventional clinical trial or a non-interventional clinical study (such as an observational cohort). The key constraint is that the application under this FOA must be for an ancillary mechanistic study and cannot propose a new clinical trial as the funded activity.
Are clinical trials allowed under this FOA?
No. The FOA is labeled "R01 Clinical Trial Not Allowed," meaning the proposed R01 project itself must not be a clinical trial. The funded work must be an ancillary mechanistic study rather than a newly proposed clinical trial.
What kinds of research questions is NIAMS looking for?
NIAMS is looking for hypothesis-driven mechanistic questions that can take advantage of the parent project's existing resources. Examples mentioned in the opportunity include studies that interrogate disease pathways, immune mechanisms, tissue biology, biomarker dynamics, or other biologic processes relevant to NIAMS mission areas.
What NIAMS mission areas are relevant for this FOA?
The opportunity is oriented toward NIAMS portfolio areas, including arthritis and rheumatic diseases, musculoskeletal biology and disorders, and skin biology and diseases.
How must the ancillary study relate to the parent project?
The ancillary work is expected to be tightly linked to the parent project in a way that meaningfully increases the scientific value of that parent effort. In practical terms, the ancillary study should use the parent project's well-characterized participants, established protocols, clinical data systems, and biospecimen pipelines to enable deeper mechanistic investigation and to sharpen interpretation of the parent project's clinical outcomes.
What does the FOA mean by "time-sensitive"?
It emphasizes that the mechanistic opportunity is tied to the ongoing timeline of the parent clinical project (for example, participants being seen now, samples being collected now, or clinical data accruing now). The opportunity is designed to support add-on work that needs to happen during the active window of the parent project.
Is there an accelerated review and award process?
Yes. The FOA emphasizes an accelerated review and award process, with the goal of moving strong applications forward quickly so investigators can capture perishable opportunities linked to the active clinical project.
What is the main rationale behind this funding opportunity?
The FOA is described as a "leverage what already exists" mechanism. NIAMS aims to maximize return on investment by enabling researchers to build on operational cohorts and infrastructure that are already funded, rather than duplicating recruitment, site setup, and data collection in a separate grant.
What is the intended payoff or impact of funded projects?
The intended payoff is a stronger mechanistic understanding of diseases or organ systems in NIAMS's portfolio, with downstream potential to uncover new diagnostic markers, therapeutic targets, or prevention strategies. The FOA frames the goal as mechanistic add-ons that improve interpretation of clinical outcomes and expand translational impact, not simply extra measurements for their own sake.
What grant mechanism is used?
This opportunity uses the NIH R01 grant mechanism.
Which NIH Institute is sponsoring this opportunity?
The sponsoring Institute is NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
What activity category and CFDA number are associated with this FOA?
The activity category is listed as "Health," and the CFDA number is 93.846.
What is the award ceiling for this funding opportunity?
The opportunity lists an award ceiling of $300,000 (as provided in the source text).
Who is eligible to apply as an organization?
Eligibility is broad and includes many U.S.-based organizations. The FOA lists eligible applicants such as state, county, city, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses.
Does the FOA include underserved-serving institutions and community-connected organizations?
Yes. The FOA explicitly includes institution and organization types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, and certain tribal governments and tribal organizations.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are listed among eligible applicant categories.
Can a non-U.S. (foreign) organization apply as the applicant?
No. Non-domestic (non-U.S.) entities and non-U.S. institutions are not eligible to apply as the applicant organization under this opportunity.
Can a non-domestic component of a U.S. organization apply?
No. Non-domestic components of U.S. organizations are not eligible to apply as the applicant.
Are foreign collaborations allowed at all?
Yes, in a limited sense. While the primary applicant organization must be domestic, "foreign components" as defined by NIH policy are allowed. This means a U.S. applicant may include specific foreign activities or collaborations when justified and consistent with NIH rules.
Does the FOA support launching a new cohort or building brand-new clinical infrastructure?
The FOA is designed to capitalize on existing resources from an already running clinical project (participants, infrastructure, data systems, and biospecimen pipelines). It emphasizes avoiding duplication of recruitment, site setup, and data collection that would occur in a separate standalone project.
What is the official title of the funding opportunity?
The FOA is titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)."
What is the FOA number?
The FOA number is RFA-AR-20-001.
What was the original closing date listed for this opportunity?
The opportunity had an original closing date of December 1, 2020.
Browse more opportunities from the same category: Health
Next opportunity: Cooperative Agreement for Student Interns for Natural and Cultural Resource Conservation Projects
Previous opportunity: Biology of Bladder Cancer (R21 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AR 20 001
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AR 20 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) Apply for RFA AR 20 002 Funding Number: RFA AR 20 002 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (SBIR) (R43 - Clinical Trial Not Allowed) Apply for RFA AR 20 003 Funding Number: RFA AR 20 003 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| "HEAL Initiative: Limited Competition: Resource Coordinating Center for Pragmatic and Implementation Studies for the Management of Pain (PRISM) to Reduce Opioid Prescribing (U24 Clinical Trial Not Allowed)" Apply for RFA AT 19 011 Funding Number: RFA AT 19 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV/AIDS Clinical Trials Units (UM1 Clinical Trial Required) Apply for RFA AI 19 045 Funding Number: RFA AI 19 045 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HLA and KIR Region Genomics in Immune-Mediated Diseases (U19 Clinical Trial Not Allowed) Apply for RFA AI 19 044 Funding Number: RFA AI 19 044 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed) Apply for PAR 19 266 Funding Number: PAR 19 266 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed) Apply for PAR 19 265 Funding Number: PAR 19 265 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models (R13 Clinical Trial Not Allowed) Apply for PAR 19 268 Funding Number: PAR 19 268 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Medicare Model Guidelines, Version 8 Apply for CMS 1C0 19 001 Funding Number: CMS 1C0 19 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $100,000 |
| HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed) Apply for PAR 19 267 Funding Number: PAR 19 267 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lucidity in Dementia (R21/R33 Clinical Trial Optional) Apply for RFA AG 20 017 Funding Number: RFA AG 20 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lucidity in Dementia (R21 Clinical Trial Optional) Apply for RFA AG 20 016 Funding Number: RFA AG 20 016 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed) Apply for PAR 19 269 Funding Number: PAR 19 269 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed) Apply for RFA GM 19 002 Funding Number: RFA GM 19 002 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Summer Research Training in Aging for Medical Students (T35 Clinical Trial Not Allowed) Apply for RFA AG 20 008 Funding Number: RFA AG 20 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pragmatic Trials of Managing Multimorbidity in Alzheimer's Disease (R61/R33 Clinical Trial Required) Apply for RFA AG 20 029 Funding Number: RFA AG 20 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54 Clinical Trial Not Allowed) Apply for RFA NS 19 019 Funding Number: RFA NS 19 019 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Private Sector Partnership Addressing Emerging Zoonoses and Antimicrobial Resistance Apply for GH BAA 2018 ADDENDUM02 Funding Number: GH BAA 2018 ADDENDUM02 Agency: Agency for International Development Category: Health Funding Amount: $40,000,000 |
| NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) Apply for PAR 19 281 Funding Number: PAR 19 281 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not Allowed) Apply for RFA RM 19 004 Funding Number: RFA RM 19 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AR 20 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.